Can PharmaEssentia turn ropeginterferon into a broader myeloproliferative neoplasm franchise?
PharmaEssentia’s ET data arrive before a key FDA date. Ropeginterferon could shift timing, sequencing, and risk thinking in MPN care.
Can Jakafi XR defend Incyte’s ruxolitinib franchise as dosing convenience becomes strategic?
Jakafi is mature, but dosing still matters. Incyte’s Jakafi XR approval could extend ruxolitinib’s strategic life in hematology.
PharmaEssentia expands beyond Taiwan with Puerto Rico plant as BESREMi growth plans widen
PharmaEssentia’s Puerto Rico facility could reshape BESREMi supply resilience and U.S. expansion. Read what this means for biologics strategy.
Can AN2 Therapeutics reposition epetraborole for polycythemia vera and reshape hematocrit control strategies?
AN2 Therapeutics plans a Phase 2 trial of epetraborole for polycythemia vera. Explore what this strategy could mean for future hematology treatments.
PharmaEssentia Corporation secures Japan approval for high-dose BESREMi regimen in polycythemia vera
Japan approves high-dose BESREMi regimen for polycythemia vera. Read the full analysis on safety, adoption, and what clinicians will watch next.
Takeda and Protagonist near FDA decision on novel PV therapy rusfertide
FDA grants Priority Review to rusfertide for polycythemia vera. Discover what this means for treatment standards and market dynamics.
How Prelude Therapeutics is advancing a JAK2 JH2 strategy into the clinic after FDA IND clearance
FDA clears Prelude Therapeutics’ IND for PRT12396. Discover what this mutant-selective JAK2 approach could change for MPN drug development.